Search Drug Information, Interactions, Images, Dosage & Side Effects

Ondansetron shows potential in irritable bowel syndrome with diarrhoea 27 Mar 2023
A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

VANGUARD sets the stage for a novel biologic in HAE

27 Mar 2023

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

26 Mar 2023

Maternal Crohn’s disease ups risk of infection in offspring

26 Mar 2023

Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma

25 Mar 2023

Higher infliximab concentrations tied to better outcomes in paediatric CD

25 Mar 2023

Sleep loss ups hunger-promoting hormones in adults

25 Mar 2023

Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial

25 Mar 2023

Add-on vistusertib misses mark in platinum-resistant, refractory ovarian high-grade serous carcinoma

25 Mar 2023

Atorvastatin may prevent anthracycline-associated cardiac dysfunction in lymphoma patients

25 Mar 2023

Less salt may be fatally counterproductive for people with heart failure

24 Mar 2023

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure 21 Mar 2023;
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

NCDs in Focus Act Now! Summit 2022

16 Mar 2023

Product Highlight - KANJINTI

03 Mar 2023

Product Highlight - Lit-Control Devicare pH Down

03 Mar 2023

Kanjinti

Contents : Trastuzumab

Indications/Uses : Treatment of adult patients w/ HER2 +ve metastatic breast cancer (MBC) as monotherapy in patients who have received at least 2 chemotherapy regimens for their metastatic disease (prior chemotherapy must have included at least an anthracycline & a taxane unless patients are unsuitable for these treatments; hormone-receptor +ve patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments); in combination w/ paclitaxel for patients who have not received chemotherapy for their metastatic disease & for whom an anthracycline is not suitable; in combination w/ docetaxel for patients who have not received chemotherapy for their metastatic disease; in combination w/ an aromatase inhibitor for postmenopausal patients w/ hormone-receptor +ve MBC not previously treated w/ trastuzumab. Treatment of adult patients w/ HER2 +ve early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) & RT if applicable; following adjuvant chemotherapy w/ doxorubicin & cyclophosphamide, in combination w/ paclitaxel or docetaxel; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; in combination w/ neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours >2 cm in diameter. Treatment of adult patients w/ HER2 +ve metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease in combination w/ capecitabine or 5-fluorouracil & cisplatin.

Zyphrine

Contents : Levocetirizine HCl

Indications/Uses : Relief of nasal & ocular symptoms of seasonal & perennial allergic rhinitis. Relief of symptoms of chronic idiopathic urticaria.

Zyphrine

Contents : Levocetirizine HCl

Indications/Uses : Relief of nasal & ocular symptoms of seasonal & perennial allergic rhinitis. Relief of symptoms of chronic idiopathic urticaria.

Actranex

Contents : Tranexamic acid

Indications/Uses : Treatment & prophylaxis of haemorrhage associated w/ excessive fibrinolysis. Prophylaxis of hereditary angioedema.

Actranex

Contents : Tranexamic acid

Indications/Uses : Treatment & prophylaxis of haemorrhage associated w/ excessive fibrinolysis. Prophylaxis of hereditary angioedema.

Rosuzet

Contents : Per 10/10 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 10 mg. Per 10/20 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 20 mg

Indications/Uses : Adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), LDL-C, Apo B, triglycerides (TG), & non-HDL-C, & to increase HDL-C in patients w/ primary (heterozygous familial & non-familial) hypercholesterolemia or mixed hyperlipidemia. Reduction of elevated total-C & LDL-C levels in patients w/ HoFH.

Rosuzet

Contents : Per 10/10 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 10 mg. Per 10/20 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 20 mg

Pantomide

Contents : Pantoprazole Na sesquihydrate 40 mg, domperidone 30 mg

Indications/Uses : Management of GERD; gastritis, non-ulcer dyspepsia, gastric or duodenal ulcer, dyspepsia, bloating, fullness, belching, NSAID-induced dyspepsia.

Pantomide

Contents : Pantoprazole Na sesquihydrate 40 mg, domperidone 30 mg

Indications/Uses : Management of GERD; gastritis, non-ulcer dyspepsia, gastric or duodenal ulcer, dyspepsia, bloating, fullness, belching, NSAID-induced dyspepsia.

Lit+Control+Devicare+(3+variant)_Down-4C-M1_2023

Lit-Control Devicare pH Down

Contents : L-methionine, phytin, vit A, Zn

Indications/Uses : Food supplement specifically recommended for reduction of JJ catheter calcification & infectious lithiasis/struvite.

Lit+Control+Devicare+(3+variant)_PH down_M4

Lit-Control Devicare pH Down

Contents : L-methionine, phytin, vit A, Zn

Indications/Uses : Food supplement specifically recommended for reduction of JJ catheter calcification & infectious lithiasis/struvite.

Lit+Control+Devicare+(3+variant)_4C-UP_M1-2023

Lit-Control Devicare pH Up

Contents : Theobromine, vit, minerals

Indications/Uses : Food supplement specifically recommended for uric acid lithiasis.

Lit-Control Devicare pH Up

Contents : Theobromine, vit, minerals

Indications/Uses : Food supplement specifically recommended for uric acid lithiasis.

Precedex Premix

Contents : Dexmedetomidine HCl (in 0.9% w/v NaCl)

Indications/Uses : Sedation of initially intubated & mechanically ventilated patients during treatment in an intensive care setting. Sedation/anxiolysis of non-intubated patients prior to &/or during surgical & other procedures.

Precedex Premix

Contents : Dexmedetomidine HCl (in 0.9% w/v NaCl)

Norpriexia/Norpriexia Forte

Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg

Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.

Norpriexia/Norpriexia Forte

Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg

Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.

Mistacor 40/Mistacor 80

Contents : Telmisartan

Indications/Uses : HTN as monotherapy or in combination w/ other antihypertensives.

Mistacor 40/Mistacor 80

Contents : Telmisartan

Indications/Uses : HTN as monotherapy or in combination w/ other antihypertensives.

Mepresone 40

Contents : Methylprednisolone Na succinate

Indications/Uses : Severe erythema multiforme (SJS); bronchial asthma, severe seasonal & perennial allergic rhinitis, angioneurotic edema, anaphylaxis; ulcerative colitis, Crohn's disease; aspiration of gastric contents, fulminating or disseminated TB (w/ appropriate anti-TB chemotherapy); cerebral oedema secondary to cerebral tumour acute exacerbations of multiple sclerosis superimposed on a relapsing-remitting background; TB meningitis (w/ appropriate anti-TB chemotherapy) transplantation.